Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06579014
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-27
Brief Title:
Prevalence and Prognostic Effects of Thyroid Abnormalities in Patients With Acute Coronary Syndrome
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Prevalence and Prognostic Effects of Thyroid Abnormalities in Patients With Acute Coronary Syndrome
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this observational study is knowledge of Prevalence of throid abnormalities in patients with acute coronary syndrome And prognostic effects of thyroid abnormalities in patients with acute coronary syndrome as early detection and management of thyroid abnormalities can improve clinical outcomes
Detailed Description:
Acute coronary syndrome ACS is an umbrella term used to describe a range of conditions associated with sudden reduced blood flow to the heart ACS includes conditions such as Unstable Angina Non-ST-Elevation Myocardial Infarction NSTEMI And ST-Elevation Myocardial Infarction STEMI The morbidity and mortality due to ACS are substantial-nearly half of all deaths due to coronary heart disease occur following an ACS
Thyroid abnormalities particularly hypothyroidism and hyperthyroidism are relatively common in patients with ACS Studies indicate that thyroid dysfunction can affect cardiovascular health influencing the risk and prognosis of ACS Reports suggest prevalence rates of Hypothyroidism 10-20 and Hyperthyroidism range from 1-5 in ACS patients
Hypothyroidism is associated with elevated cholesterol levels increased vascular stiffness and heightened inflammation can lead to reduced cardiac output and heart rate and increased incidence of heart failure and arrhythmias all of which can exacerbate coronary artery disease and contributing to worse outcomes during ACS event Hypothyroid patients often have a slower recovery and poorer response to standard ACS treatments including thrombolytics and antiplatelet therapy
Hyperthyroidism raises heart rate and contractility leading to increased myocardial oxygen demand which can worsen ischemia during ACS Patients are more susceptible to arrhythmias which can complicate ACS and lead to higher morbidity and mortality Hyperthyroidism can cause vascular endothelial dysfunction increasing the risk of thrombotic events during ACS and Patients may respond differently to standard ACS therapies necessitating careful monitoring and potential adjustment of treatment strategies
Patients with concurrent thyroid dysfunction often experience higher morbidity and mortality rates So thyroid function should be routinely assessed in ACS patients as early detection and management of thyroid abnormalities can improve clinical outcomes
Thyroid abnormalities particularly hypothyroidism and hyperthyroidism are relatively common in patients with ACS Studies indicate that thyroid dysfunction can affect cardiovascular health influencing the risk and prognosis of ACS Reports suggest prevalence rates of Hypothyroidism 10-20 and Hyperthyroidism range from 1-5 in ACS patients
Hypothyroidism is associated with elevated cholesterol levels increased vascular stiffness and heightened inflammation can lead to reduced cardiac output and heart rate and increased incidence of heart failure and arrhythmias all of which can exacerbate coronary artery disease and contributing to worse outcomes during ACS event Hypothyroid patients often have a slower recovery and poorer response to standard ACS treatments including thrombolytics and antiplatelet therapy
Hyperthyroidism raises heart rate and contractility leading to increased myocardial oxygen demand which can worsen ischemia during ACS Patients are more susceptible to arrhythmias which can complicate ACS and lead to higher morbidity and mortality Hyperthyroidism can cause vascular endothelial dysfunction increasing the risk of thrombotic events during ACS and Patients may respond differently to standard ACS therapies necessitating careful monitoring and potential adjustment of treatment strategies
Patients with concurrent thyroid dysfunction often experience higher morbidity and mortality rates So thyroid function should be routinely assessed in ACS patients as early detection and management of thyroid abnormalities can improve clinical outcomes
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None